v3.26.1
REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation of Revenue [Line Items]    
Total revenues $ 6,960 $ 6,667
U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,926 4,668
Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,144 1,084
Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 889 915
Total product sales    
Disaggregation of Revenue [Line Items]    
Total revenues 6,946 6,613
Total product sales | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,926 4,631
Total product sales | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,137 1,073
Total product sales | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 883 909
Total HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 5,030 4,587
Total HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,004 3,664
Total HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 607 553
Total HIV | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 419 370
Biktarvy    
Disaggregation of Revenue [Line Items]    
Total revenues 3,361 3,150
Biktarvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 2,573 2,474
Biktarvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 437 375
Biktarvy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 352 301
Descovy    
Disaggregation of Revenue [Line Items]    
Total revenues 807 586
Descovy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 761 538
Descovy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 23 21
Descovy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 23 27
Genvoya    
Disaggregation of Revenue [Line Items]    
Total revenues 264 364
Genvoya | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 215 305
Genvoya | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 33 40
Genvoya | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 16 19
Odefsey    
Disaggregation of Revenue [Line Items]    
Total revenues 221 281
Odefsey | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 153 215
Odefsey | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 59 57
Odefsey | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 9 10
Symtuza - Revenue share    
Disaggregation of Revenue [Line Items]    
Total revenues 138 114
Symtuza - Revenue share | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 107 82
Symtuza - Revenue share | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 28 29
Symtuza - Revenue share | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 3 3
Yeztugo    
Disaggregation of Revenue [Line Items]    
Total revenues 166 0
Yeztugo | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 158 0
Yeztugo | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Yeztugo | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 7 0
Other HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 73 91
Other HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 36 50
Other HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 27 31
Other HIV | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 9 10
Total Oncology    
Disaggregation of Revenue [Line Items]    
Total revenues 810 757
Total Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 403 381
Total Oncology | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 278 255
Total Oncology | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 129 121
Total Cell Therapy    
Disaggregation of Revenue [Line Items]    
Total revenues 407 464
Total Cell Therapy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 150 200
Total Cell Therapy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 183 180
Total Cell Therapy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 74 84
Tecartus    
Disaggregation of Revenue [Line Items]    
Total revenues 75 78
Tecartus | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 30 40
Tecartus | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 37 31
Tecartus | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 8 8
Yescarta    
Disaggregation of Revenue [Line Items]    
Total revenues 332 386
Yescarta | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 120 160
Yescarta | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 146 149
Yescarta | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 67 77
Trodelvy    
Disaggregation of Revenue [Line Items]    
Total revenues 402 293
Trodelvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 253 181
Trodelvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 95 75
Trodelvy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 54 37
Total Liver Disease    
Disaggregation of Revenue [Line Items]    
Total revenues 767 758
Total Liver Disease | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 362 335
Total Liver Disease | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 170 168
Total Liver Disease | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 235 256
Livdelzi    
Disaggregation of Revenue [Line Items]    
Total revenues 133 40
Livdelzi | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 115 40
Livdelzi | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 18 0
Livdelzi | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Sofosbuvir/Velpatasvir    
Disaggregation of Revenue [Line Items]    
Total revenues 283 346
Sofosbuvir/Velpatasvir | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 141 166
Sofosbuvir/Velpatasvir | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 60 80
Sofosbuvir/Velpatasvir | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 82 99
Vemlidy    
Disaggregation of Revenue [Line Items]    
Total revenues 237 252
Vemlidy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 91 100
Vemlidy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 13 12
Vemlidy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 132 140
Other Liver Disease    
Disaggregation of Revenue [Line Items]    
Total revenues 114 121
Other Liver Disease | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 15 28
Other Liver Disease | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 78 76
Other Liver Disease | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 21 17
Veklury    
Disaggregation of Revenue [Line Items]    
Total revenues 144 302
Veklury | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 112 199
Veklury | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 14 22
Veklury | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 18 82
Total Other    
Disaggregation of Revenue [Line Items]    
Total revenues 196 209
Total Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 46 52
Total Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 67 76
Total Other | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 83 81
AmBisome    
Disaggregation of Revenue [Line Items]    
Total revenues 138 139
AmBisome | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 7 5
AmBisome | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 59 67
AmBisome | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 72 66
Other    
Disaggregation of Revenue [Line Items]    
Total revenues 58 70
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 39 47
Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 8 9
Other | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 11 14
Royalty, contract and other revenues    
Disaggregation of Revenue [Line Items]    
Total revenues 14 54
Royalty, contract and other revenues | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 0 37
Royalty, contract and other revenues | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 8 11
Royalty, contract and other revenues | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues $ 6 $ 6